Log in or Sign up for Free to view tailored content for your specialty!
Autoimmune/Cholestatic/Biliary Diseases News
Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC
The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for the treatment of primary biliary cholangitis, the company announced in a press release.
Ocaliva down but not out: A timeline of FDA troubles for a once-promising PBC contender
Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.
FDA: Ocaliva still linked to ‘serious liver injury’ in PBC, even without cirrhosis
The FDA has issued a safety alert warning that obeticholic acid carries an increased risk for “serious liver injury” among patients with primary biliary cholangitis, even those without advanced cirrhosis.
Log in or Sign up for Free to view tailored content for your specialty!
Researchers seek to improve the 'diagnostic odyssey' of infant biliary atresia evaluations
SAN DIEGO — A new ultrasound approach may help more quickly and less invasively identify infants with biliary atresia, according to research presented at The Liver Meeting.
Patients with PBC who failed with obeticholic acid may still achieve ‘some benefit’
SAN DIEGO — Patients with primary biliary cholangitis who were incomplete responders to obeticholic acid may still demonstrate improvement in inflammatory markers and fibrosis scores, according to research presented at The Liver Meeting.
Livdelzi reduces cholestatic, liver injury markers in patients with PBC and cirrhosis
SAN DIEGO — Livdelzi appeared safe and well-tolerated and reduced markers of cholestasis and liver injury in patients with primary biliary cholangitis, including those with compensated cirrhosis, according to a presenter.
Mycophenolate ‘comparable, if not better’ than azathioprine for autoimmune hepatitis
PHILADELPHIA — Mycophenolate mofetil appeared to be more efficacious and tolerable than azathioprine in patients with autoimmune hepatitis, especially among those aged older than 50 years and with lower IgG levels, according to a presenter.
Pharmacotherapy for alcohol use disorder ‘underutilized’ in at-risk populations
PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented at the ACG Annual Scientific Meeting.
VIDEO: ‘Encouraging’ safety data on Livdelzi in primary biliary cholangitis, cirrhosis
PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual Scientific Meeting investigating the use of Livdelzi in patients with primary biliary cholangitis and cirrhosis.
VIDEO: Treating autoimmune hepatitis with mycophenolate ‘still a cautionary tale’
PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, speaks with Healio about findings from a systemic review and meta-analysis on the efficacy of mycophenolate mofetil compared with azathioprine for autoimmune hepatitis.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read